📊 CLRB Key Takeaways
Is Cellectar Biosciences, Inc. (CLRB) a Good Investment?
Cellectar Biosciences is a pre-revenue pharmaceutical company with severe operational losses (-$23M operating income) and negative free cash flow (-$23.1M) that will deplete its $13.2M cash position within months at current burn rate. The company demonstrates no revenue generation capability, negative profitability metrics across all measures (ROE: -255%, ROA: -145%), and faces an existential liquidity crisis despite manageable debt levels.
Cellectar Biosciences shows the classic profile of a pre-revenue biotech with no operating income base, deeply negative cash flow, and very weak returns on capital. While the latest period shows a narrower net loss and a relatively clean balance sheet, the cash burn is far too high versus cash on hand, implying substantial financing dependence unless fundamentals improve quickly.
Why Buy Cellectar Biosciences, Inc. Stock? CLRB Key Strengths
- Low debt burden with debt-to-equity ratio of 0.04x reducing financial distress risk
- Adequate short-term liquidity with current ratio of 2.96x and quick ratio of 2.96x
- Net income loss improved 51.1% year-over-year indicating reduced burn trajectory
- Balance sheet leverage is low, with debt/equity of just 0.04x and minimal long-term debt
- Liquidity ratios are still acceptable at 2.96x, indicating near-term obligations are currently covered
- Net loss improved year over year, suggesting some expense control or non-operating improvement versus the prior period
CLRB Stock Risks: Cellectar Biosciences, Inc. Investment Risks
- No revenue generation with operating losses of $23M annually indicating failed commercialization or product pipeline
- Critical cash runway of approximately 6 months at current $23.1M quarterly operating burn rate
- Severe negative returns on assets (-145.5%) and equity (-255.2%) demonstrating value destruction and inefficient capital deployment
- Zero insider buying activity suggests management lacks confidence in turnaround prospects
- Pre-revenue stage with no clear path to profitability or cash flow positivity in near term
- No revenue base is reported, making growth quality and business model validation highly uncertain
- Operating cash flow of -$23.12M against only $13.20M in cash implies a short cash runway and likely future capital raising
- Profitability remains deeply negative, with ROE of -255.2% and ROA of -145.5%, indicating poor capital efficiency
Key Metrics to Watch
- Monthly operating cash burn rate and cash runway to depletion
- Revenue generation milestones or clinical trial outcomes validating product viability
- Capital raise activities and dilution impact from necessary financing
- Operating expense reduction initiatives and pathway to profitability
- Quarterly operating cash burn relative to cash balance
- Any emergence of recurring revenue or major reduction in operating losses
Cellectar Biosciences, Inc. (CLRB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.96x current ratio provides a solid financial cushion.
CLRB Profit Margin, ROE & Profitability Analysis
CLRB vs Healthcare Sector: How Cellectar Biosciences, Inc. Compares
How Cellectar Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cellectar Biosciences, Inc. Stock Overvalued? CLRB Valuation Analysis 2026
Based on fundamental analysis, Cellectar Biosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cellectar Biosciences, Inc. Balance Sheet: CLRB Debt, Cash & Liquidity
CLRB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cellectar Biosciences, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-41.89 indicates the company is currently unprofitable.
CLRB Revenue Growth, EPS Growth & YoY Performance
Cellectar Biosciences, Inc. Dividends, Buybacks & Capital Allocation
CLRB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cellectar Biosciences, Inc. (CIK: 0001279704)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CLRB
What is the AI rating for CLRB?
Cellectar Biosciences, Inc. (CLRB) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 89% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CLRB's key strengths?
Claude: Low debt burden with debt-to-equity ratio of 0.04x reducing financial distress risk. Adequate short-term liquidity with current ratio of 2.96x and quick ratio of 2.96x. ChatGPT: Balance sheet leverage is low, with debt/equity of just 0.04x and minimal long-term debt. Liquidity ratios are still acceptable at 2.96x, indicating near-term obligations are currently covered.
What are the risks of investing in CLRB?
Claude: No revenue generation with operating losses of $23M annually indicating failed commercialization or product pipeline. Critical cash runway of approximately 6 months at current $23.1M quarterly operating burn rate. ChatGPT: No revenue base is reported, making growth quality and business model validation highly uncertain. Operating cash flow of -$23.12M against only $13.20M in cash implies a short cash runway and likely future capital raising.
What is CLRB's revenue and growth?
Cellectar Biosciences, Inc. reported revenue of N/A.
Does CLRB pay dividends?
Cellectar Biosciences, Inc. does not currently pay dividends.
Where can I find CLRB SEC filings?
Official SEC filings for Cellectar Biosciences, Inc. (CIK: 0001279704) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CLRB's EPS?
Cellectar Biosciences, Inc. has a diluted EPS of $-8.35.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CLRB a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Cellectar Biosciences, Inc. has a STRONG SELL rating with 89% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CLRB stock overvalued or undervalued?
Valuation metrics for CLRB: ROE of -255.2% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CLRB stock in 2026?
Our dual AI analysis gives Cellectar Biosciences, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CLRB's free cash flow?
Cellectar Biosciences, Inc.'s operating cash flow is $-23.1M, with capital expenditures of $5.9K.
How does CLRB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -255.2% (avg: 15%), current ratio 2.96 (avg: 2).